摘要:
Compounds of the formula (I), in which R1, R2, m, Q and B have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
摘要:
Compounds of the formula I in which R1, R2, R3, R4′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
摘要:
Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
摘要:
Novel compounds of the formula (I), in which R, R1, R2 and R3 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
摘要:
Novel squaric acid compounds of the formula (I), in which R, R1, R2, R2′, R2″, R3, B, B′ and X have the meanings indicated in Claim 1, are inhibitors of CHK1 CHK2 and SGK kinases and can be used for the treatment of diseases and complaints such as cancer, diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.
摘要:
Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.
摘要:
Use of compounds of the formula (I) in which D, E, G, W, X, Y, T, R1 and R2 have the meaning indicated in Patent Claim 1, for the prophylaxis and/or therapy of thromboembolic diseases
摘要:
Compounds of the formula (I), in which D, R1, R2 and n are defined in Claim 1, are potent 5-HT1A agonists and 5-HT reuptake inhibitors and are suitable for the treatment of depression, anxiety states, panic attacks, obsessive-compulsive disorders, psychiatric illnesses, cerebral infarction, cerebral ischaemia, tension states, side-effects in the treatment of high blood pressure, for the prophylaxis and therapy of cerebral illnesses, acromegaly, hypogonadism, secondary amenorrhoea, premenstrual syndrome, undesired puerperal lactation, pain, sleep disorders, narcolepsy, bipolar illnesses, mania, dementia, addiction illnesses, sexual dysfunction, eating disorders, obesity or fibromyalgia
摘要翻译:其中D,R 1,R 2和n在权利要求1中定义的式(I)化合物是有效的5-HT 1A, SUB +激动剂和5-HT再摄取抑制剂,适用于治疗抑郁症,焦虑症,恐慌发作,强迫症,精神疾病,脑梗塞,脑缺血,紧张状态,高血压治疗中的副作用 压力,用于预防和治疗脑疾病,肢端肥大症,性腺机能减退,继发性闭经,经前期综合征,不期望的产后泌乳,疼痛,睡眠障碍,发作性睡眠,双相性疾病,躁狂症,痴呆,成瘾症,性功能障碍,进食障碍,肥胖症或 纤维肌痛
摘要:
Novel compounds of the formula (I) in which Het, R1, R2 and R3 have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
摘要:
Novel compounds of the formula (I), in which R, R1, R2 and R3 have the meanings indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.